IAS 2025  13. IAS Konferenz in Kigali 

Die Konferenz fand nicht nur in Afrika statt, sie stand auch ganz im Zeichen von HIV in Afrika. Viele Arbeiten beschäftigten sich mit den Auswirkungen der finanziellen Kürzungen, der Zukunft der Prävention und den Effekten der ART im afrikanischen Setting. Darüber hinaus wurden aber auch neue Medikamente, Kohorten-Auswertungen und neue Leitlinien vorgestellt. Ein Bericht über den Kongress erscheint in Infection&more 3/2025


PDF/PPT zum Download ppt pdf

Gilead ViiV

GileadGilead Abstracts HIV -  IAS 2025 – Internal Datasets



B/F/TAF

Long-term Persistence, Effectiveness, Safety, and Metabolic Impact of B/F/TAF Fixed-Dose Combination in TN and Experienced PWH in a Large Latin American Cohort
BFTAF/Cecchini_IAS2025_Poster_EP0173.pdf
Real-World Liver Outcomes in PWH and Hepatitis B Virus Receiving ART
BFTAF/Chuo_IAS2025_Poster_WEPEC045.pdf
HIV viewpoints: Survey on the Experiences of PWH Around the World
BFTAF/Guillaume_IAS2025_Poster_THPED077.pdf

F/TAF

Efficacy and Safety of F/TAF plus Cobicistat BPI in Children with HIV-1 Aged 2-<12 Years and Weighing 14-<40 kg: Week 48 Outcomes
FTAF/Mujuru_IAS2025_Poster_TUPEB041.pdf

PREVENTION

Lenacapavir Dosing in Special Situations: Tuberculosis and Beyond
Prevention/Bekker_IAS2025_Oral LB.pdf
Inclusion of Pregnant and Lactating People in the Purpose 1 Study: Efficacy, Safety, and PK
Prevention/Bekker_IAS2025_Oral_C0504.pdf
Protecting Mothers and Babies From HIV: Lessons From the PURPOSE 1 Study of Lenacapavir for PrEP
Prevention/Bekker_Summary_IAS2025_Summary_Final_draft_15July25_Unedit.pdf
Efficacy, Safety, and PK of Twice-Yearly Subcutaneous Lenacapavir for Prep Among Adolescents and Young People in the Phase 3 Trials PURPOSE 1 and PURPOSE 2
Prevention/Gill_IAS2025_Oral_C0503.pdf
Protecting Young People From HIV: Lessons From the PURPOSE 1 and 2 Studies of Lenacapavir for PrEP
Prevention/Gill_Summary_IAS2025_P1_P2_Young_people__Final_draft_15Jul.pdf
Estimation of the Counterfactual HIV Incidence in the PURPOSE Trials
Prevention/Kelley_IAS2025_Oral_C0505.pdf
Predictors of HIV Prep Preferences Using the Health Belief Model: Twice-Yearly Subcutaneous Lenacapavir vs Daily Pills in the PURPOSE 1 Trial
Prevention/Mansoor_IAS2025_Poster_TUPEC057.pdf
Preference for Twice-Yearly Injections vs Daily Oral Pills for HIV Prep in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People Enrolled in PURPOSE 2
Prevention/Mngadi_IAS2025_Oral_C0502.pdf
Exploratory Qualitative Analysis of the Acceptability of HIV Prevention Methods Among Pregnant and Lactating Women Interviewed During the Randomized Blinded Phase of PURPOSE 1
Prevention/Nyamaizi_IAS2025_Poster_EP0725.pdf
Factors Impacting Women's Choice of Prep use After the Randomized Blinded Phase of PURPOSE 1
Prevention/Palanee-Phillips_IAS2025_Poster_WEPED077.pdf

LEN HIV TREATMENT PIPELINE: LEN + bNAbs

HIV-Specific T-cell Responses in Suppressed PWH Receiving Lenacapavir, Teropavimab, and Zinlirvimab
LEN HIV Tx Pipeline LEN+bNAbs/Cai_IAS2025_Oral_OAA0205.pdf
Satisfaction, Preference, and Health-Related Quality of Life Changes Using HIV-Specific PRO Measures with a Novel, Twice-Yearly Administered HIV-1 Treatment Regimen
LEN HIV Tx Pipeline LEN+bNAbs/Gaur A_IAS 2025_Poster_THPEB038.pdf

HIV CURE

Vesatolimod Pharmacodynamic Responses in a Trial of Vesatolimod and bNAbs in Early-Treated South African Women with Clade C HIV-1
HIV Cure/Cai_IAS2025_Poster_WEPEB018.pdf
Synergizing Expertise: Lessons Learned from Conducting the first HIV Cure Interventional Trial in Africa with Collaboration Between Academia, Government, and Industry
HIV Cure/Dong_IAS2025_Poster_EP1003.pdf

HIV TREATMENT (OTHER)

Biomarkers Associated with Risk of Negative Clinical Outcomes in PWH on Opioid Replacement Therapy
HIV Tx other/Azzoni_IAS2025_Poster_EP0081.pdf

B/F/TAF

Predictors of Weight Gain among PWH Over 3-year Period
BFTAF/Elion_IAS2025_Oral_OAB0204.pdf
Evaluating Social Support, Psychological Distress, and HIV-Related Stigma in a Cohort of ART-Experienced Migrants Switched to B/F/TAF in Montreal, Canada - the ASAP-Switch Study
BFTAF/Godin_IAS2025_Poster_EP0239.pdf
Co-morbidities in HIV Positive and HIV NegativeIndividuals Aged ≥60 Years - A Comparative Analysis
BFTAF/Ombajo_IAS2025_Poster_TUPEB021.pdf

LENACAPAVIR HIV TREATMENT

Capsid Inhibition with Lenacapavir in HIV-1 Infection: Real-Life Results From the French Compassionate Use Program
LEN HIV Tx/Delaugerre_IAS2025_Poster_EP0195.pdf

HIV PREVENTION/PrEP

"It Seemed Like Something I Couldn't Really Ask for:" A Qualitative Analysis of Cis- and Transgender Women's Experiences Along the PrEP Cascade in the South Bronx, NYC
HIV Prevention PrEP/Abularrage_IAS2025_Poster_EP0529.pdf
Prescription of HIV Pre-Exposure Prophylaxis and HIV Incidence in a Cohort of Women with Severe Mental Illnesses in the U.S.
HIV Prevention PrEP/Bunting_IAS2025_Poster_EP0337.pdf
Differential HIV Incidence and PrEP-to-Need Ratio Among a Large, Diverse Cohort of People With Mental Illnesses in the U.S.
HIV Prevention PrEP/Bunting_IAS2025_Poster_TUPEC053.pdf
HIV Incidence and Use of Pre-Exposure Prophylaxis Among a Large, National Cohort of People with Bipolar Disorder
HIV Prevention PrEP/Bunting_IAS2025_Poster_WEPEC053.pdf
Making PrEP Smart: Persistence, Use, and Acceptability of a PrEP Adherence and HIV-Self Testing App Among Women in the South Bronx, NYC
HIV Prevention PrEP/Wright_IAS2025_Poster_EP0866.pdf





ViiV HealthcareViiV Healthcare

CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment

Perspectives of healthcare providers on long-acting injectable cabotegravir and rilpivirine delivery in clinic and community settings in the UK: longitudinal survey findings from the ILANA study*
Chloe Orkin et al. - E-Poster

View Abstract

The power of choice: strong preference for CAB+RPV LA following rapid suppression with DTG/3TC in newly diagnosed people living with HIV
Franco Felizarta et al. - E-Poster

View Poster

Real-world Effectiveness of CAB+RPV LA in Individuals with HIV Viremia at Therapy Initiation
Ricky K. Hsu et al. - Oral Presentation

View Poster

Clinical Outcomes Among Women in the OPERA Cohort Initiating CAB+RPV LA with Viral Loads ≥ 50 copies/mL
Jessica Altamarino et al. - In-person Poster

View Poster

High virologic suppression and few virologic failures with Long-Acting Cabotegravir + Rilpivirine in Treatment Experienced Virologically Suppressed Individuals from COMBINE-2 cohort in Europe
Anton Pozniak et al. - E-Poster

View Poster

Perspectives of people with HIV (PWH) 24 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)
Franco Felizarta et al. - In-person Poster

View Poster

Clinical Outcomes at Month 24 After Initiation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND)
Gary Blick et al. - E-Poster

View Poster

24-month outcomes of cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: effectiveness, adherence to injections, and participant-reported outcomes from people with HIV-1 in the German CARLOS cohort
Christoph Wyen et al. - In-person Poster

View Poster

Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Cabotegravir (CAB): Data from The Antiretroviral Pregnancy Registry (APR)
Vani Vannappagari et al. - Oral Presentation

View Poster

DOLUTEGRAVIR-based regimens

Virological outcomes of adolescents switched to dolutegravir based regimens at Botswana-Baylor Children's Clinical Centre of Excellence (BBCCCOE), 2016 to 2023*
John Farirai et al. - E-Poster

View Abstract

Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial*
James Wyncoll et al. - Oral Presentation

View Abstract

Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline transmitted drug-resistance mutations: a subanalysis of the D2ARLING study*
E. Cordova et al. - E-Poster

View Abstract

Patient-Reported Outcomes among virally suppressed people living with HIV switching to dolutegravir/lamivudine vs. continuing bictegravir/emtricitabine/tenofovir alafenamide from the randomized DYAD study*
Charlotte-Paige Rolle et al. - E-Poster

View Abstract

Impact of Dual Therapy on Weight Gain and Metabolic Outcomes in Naïve People living with HIV (PLHIV) with CD4 Counts <200 Cells/mm3: Findings from the DOLCE Study*
M. Figueroa et al. - E-Poster

View Abstract

The Impact of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-Positive People with CD4 <200 Cells/mm3 Initiating Dolutegravir/Lamivudine Dual Therapy: DOLCE Study Findings*
C. Brites et al. - In-person Poster

View Abstract

Is exclusion of tenofovir from antiretroviral regimens safe in Africa: insights on hepatitis B from the switch to DTG/3TC (Sungura) study*
Loice Achieng Ombajo et al. - In-person Poster

View Abstract

Efficacy and safety of switching to dolutegravir/lamivudine dual therapy from bictegravir/emtricitabine/tenofovir alafenamide among virally suppressed older adults ≥60 years: week 24 results from the Sungura study*
Loice Achieng Ombajo et al. - In-person Poster

View Abstract

Rapid virologic suppression with DTG/3TC facilitates early switch to CAB+RPV LA for treatment-naive people living with HIV: Suppression Phase outcomes from the Phase 3b VOLITION study
Ezequiel Córdova et al. - In-person Poster

View Poster

*denotes ViiV-supported investigator led and collaborative studies


Über den untenstehenden Link erhalten Sie Zugriff auf alle von ViiV gesponserten sowie von ViiV-unterstützten Kooperationsstudien, die beim IAS 2025 präsentiert wurden – darunter auch Studien zu Cabotegravir zur Prävention und weitere HIV-bezogene Publikationen.


Alle Poster & Abstracts

DAIG LogoDGI LogoDSTIG LogoPEG Logo

Meldungen

  • APAT

    14. August 2025: Vancomycin besser im PICC oder Midline-Katheter? weiter

  • Hib-Infektion

    13. August 2025: Infektionen in Hamburg weiter

  • Reserveantibiotika

    13. August 2025: Aktualisierung der Einstufung weiter

  • Candida auris

    11. August 2025: Neues zum Screening weiter

  • Sepsis

    11. August 2025: DigiSep unter den Finalisten des MSD-Gesundheitspreises weiter

  • Newletter online

    Jeden Monat akutelle Informationen rund ums Thema HIV und sexuell übertragbare Erkrankungen.

    Für Ärzt_innen, Menschen mit HIV und alle Interessierten.

    Anmeldung hier

  • Sepsis

    11. August 2025: Neue S3-Leitlinie weiter

  • Mikrobiom

    09. August 2025: DZIF fördert Entwicklung eines Klebsiella oxytoca-Biotherapeutikums weiter

  • Tuberkulose

    09. August 2025: Quantiferon-Test bei Immunschwäche nicht ausreichend weiter

  • Nipah-Virus

    07. August 2025: Erhöhte Alarmbereitschaft in Kerala/Indien weiter

  • Chikungunya

    06. August 2025: Ausbruch in Südchina weiter

  • Salmonellen

    06. August 2025: Prognose nichttyphöser Salmonellose weiter

  • Flöhe

    06. August 2025: Häufung von Floh-Fällen in Berlin weiter

  • Hepatitis E

    31. Juli 2025: Ribavirin-Dosierung bei Transplantierten weiter

  • HIV-Prävention

    31. Juli 2025: Einmalig Antikörper für Neugeborene? weiter

  • HPV

    30. Juli 2025: Beta-HPV kann bei Immunschwäche zu Hautkrebs führen weiter

Ältere Meldungen weiter

Diese Website bietet aktuelle Informationen zu HIV/Aids sowie zur HIV/HCV-Koinfektion. Im Mittelpunkt stehen HIV-Test, Symptome und Auswirkungen der HIV-Infektion, Behandlung der HIV-Infektion, HIV-Medikamente mit Nebenwirkungen und Komplikationen, Aids, Hepatitis B und C. Ein Verzeichnis der Ärzte mit Schwerpunkt HIV ergänzt das Angebot.